HIGHLIGHTS
- who: Lei Zhang from the (UNIVERSITY) have published the research: A novel, in the Journal: (JOURNAL)
- how: The results showed that the PD-L1 expression of the tumor cells was 20-30% (Fig 2) TMB was 58.58 mutations/Mb and intriguingly a novel NCOR2-NTRK1 fusion was detected . The authors used immunotherapy with PD-1 inhibitor of Camrelizumab and the targeted therapy with larotrectinib in this lung cancer patient.
SUMMARY
Of cancer cells, which do not affect the normal cells. NTRK fusions have been identified as new targets of cancer . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.